ETO Antibody

• 产品编号：CST-4498S      品牌：CST       原厂货号：4498S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

ETO抗体能够检测内源ETO蛋白。此多克隆抗体是通过合成人源对应的ETO N-末端 Ser270位点周围的肽段来免疫动物而获得。抗体是通过protein A和多肽亲和层析纯化。ETO 属于进化上保守的核因子家族。尽管没有DNA结合区域，它也被报道是作为转录的辅阻遏物(1)。它在急性骨髓性白血病中t(8;21)易位而与AML1融合导致了AML-ETO融合蛋白表达的升高(2)。AML1作为转录因子参与到所有造血细胞系的分化过程中。融合蛋白缺乏AML1的激活区域并作为显性失活的AML1而抑制AML1 的靶标基因。AML-ETO通过包括Bcl-2和增强表达的p21 waf1/cip1在内的机制也引起其他基因的激活(3,4)。AML-ETO融合蛋白被认为是导致一类有限的谱系造血干细胞的数量扩大并造成基因组的不稳定性(5)。近来染色质免疫共沉淀 (ChIP)实验证明ETO在调控Notch靶标基因中发挥了重要的作用, AML-ETO也能够破坏对Notch靶标基因的抑制(6)。因此, AML 和Notch 的靶标基因都能够被AML-ETO撤除管制和限制. 表观遗传沉默microRNA-223基因导致了对AML-ETO的激活, 并对t(8;21)白血病的分化有作用(7)。

1. Davis, J.N. et al. (2003) Gene 303, 1-10.
2. Downing, J.R. et al. (1993) Blood 81, 2860-5.
3. Klampfer, L. et al. (1996) Proc Natl Acad Sci USA 93, 14059-64.
4. Peterson, L.F. et al. (2007) Blood 109, 4392-8.
5. Elagib, K.E. and Goldfarb, A.N. (2007) Cancer Lett 251, 179-86.
6. Salat, D. et al. (2008) Mol Cell Biol 28, 3502-12.
7. Nervi, C. et al. Epigenetics 3, 1-4.

原厂资料：

Specificity / Sensitivity

ETO Antibody detects endogenous levels of ETO protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino acid sequence surrounding Ser270 of human ETO. Antibodies are purified by protein A and peptide affinity chromatography.

Background

ETO belongs to a family of evolutionarily conserved nuclear factors. Although it has no DNA binding domains it is reported to act as a transcriptional corepressor (1). It is best characterized as the fusion partner of AML1 in acute myeloid leukemia with the t(8;21) translocation which gives rise to the AML-ETO fusion protein (2). AML1 is a transcription factor that is involved in the differentiation of all hematopoietic lineages. The fusion protein lacks the activation domain of AML1 and behaves as a dominant negative AML1, repressing AML1 target genes. AML-ETO also causes activation of other genes through a mechanism that involves Bcl-2 and enhanced expression of p21 waf1/cip1 (3,4). The AML-ETO fusion protein is thought to cause the expansion of a hematopoietic stem cell population that has limited lineage commitment and genomic instability (5). Recent evidence derived from chromatin immunoprecipitation (ChIP) experiments has demonstrated that ETO may play a role in the regulation of Notch target genes, and AML-ETO has been shown to disrupt repression of Notch target genes (6). Therefore, both AML and Notch target genes are deregulated by AML-ETO. Epigenetic silencing of the microRNA-223 gene has also been attributed to activities of AML-ETO, contributing to the differentiation block in t(8;21) leukemia (7).

1. Davis, J.N. et al. (2003) Gene 303, 1-10.
2. Downing, J.R. et al. (1993) Blood 81, 2860-5.
3. Klampfer, L. et al. (1996) Proc Natl Acad Sci USA 93, 14059-64.
4. Peterson, L.F. et al. (2007) Blood 109, 4392-8.
5. Elagib, K.E. and Goldfarb, A.N. (2007) Cancer Lett 251, 179-86.
6. Salat, D. et al. (2008) Mol Cell Biol 28, 3502-12.
7. Nervi, C. et al. Epigenetics 3, 1-4.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody